Therapeutic Interventions For Pain Induced By Vincristine Treatment For Childhood Acute Lymphoblastic Leukemia (ALL) (TINALL)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Neuropathic pain / peripheral neuropathy (NP/PN) is a known painful complication of vincristine (VCR) therapy; evidence supporting the best treatment plan for pediatric patients is limited. Gabapentin is frequently used for VCR-related NP/PN, with variable dosing and scheduling regimens, and with varying measures of success. The hypothesis of the study is that gabapentin will reduce the severity of NP/PN in patients receiving vincristine during treatment for ALL on the Total XVI protocol, as measured by two outcome measures: the daily dose of morphine used as needed for pain in addition to either gabapentin or placebo, as randomized, and the pain scores assessed daily.
| Condition | Intervention | Phase |
|---|---|---|
|
Acute Lymphoblastic Leukemia Neuropathy Neuropathic Pain |
Drug: gabapentin Drug: placebo |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Supportive Care |
| Official Title: | Therapeutic Interventions For Peripheral Neuropathy/Neuropathic Pain Induced By Vincristine Treatment For Childhood Acute Lymphoblastic Leukemia (ALL) On Total XVI Protocol |
- Daily total dose of oral morphine (mg/kg/day). [ Time Frame: Daily beginning day 1 for a maximum of 21 days. ] [ Designated as safety issue: No ]A quantity measured by pill count and/or adherence interview
- Pain scores right now [ Time Frame: Daily beginning day 1 through a maximum of 21 days. ] [ Designated as safety issue: No ]A score ranging from 0 to 10, measured by age appropriate validated pain scale
- Pain score during the previous 24 hours [ Time Frame: Daily beginning day 1 through a maximum of 21 days ] [ Designated as safety issue: No ]A score ranging from 0 to 10, measured by age appropriate validated pain scale
| Estimated Enrollment: | 80 |
| Study Start Date: | January 2012 |
| Estimated Study Completion Date: | January 2016 |
| Estimated Primary Completion Date: | January 2016 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Gabapentin
Active treatment arm.
|
Drug: gabapentin
Participants randomized to the active treatment arm will receive gabapentin 20mg/kg/day PO divided into 3 doses and rounded to the nearest 100 mg for capsules and 10 mg for liquid preparation.
Other Name: Treatment Arm
|
|
Placebo Comparator: Placebo
Placebo arm.
|
Drug: placebo
Participants randomized to the placebo treatment arm will receive look-alike capsules or liquid in a respective capsule size or liquid measure equivalent to the active treatment arm, but which contain no active treatment.
Other Name: Placebo Arm
|
Detailed Description:
Patients with ALL on Total XVI who experience NP/PN after specific doses of vincristine are eligible to enroll in the study as soon as the diagnosis of NP/PN related to VCR is established. The qualifying doses of vincristine have been selected because they fall in the schedule of weekly vincristine doses as per Total XVI, and 2 additional weekly vincristine doses are anticipated according to the protocol. Participants will be randomized to receive gabapentin or placebo upon enrollment. Morphine will be available to both groups as needed for pain at any time on the study. At the time of enrollment, and daily thereafter until completion of the study drug, data will be collected for pain assessment, and the daily dose of oral morphine used will be collected. Data regarding the pain type, quality, and location, as well as treatments used to manage pain will be assessed on a daily basis for the diagnostic event and for the period following the next two administrations of VCR treated with the study drug.
Primary Objective: To assess the analgesic efficacy of gabapentin in controlling VCR-related NP/PN in participants with ALL, by comparing the morphine daily dose (mg/kg/day) used to control NP/PN as a primary or a rescue regimen in the gabapentin vs. placebo groups.
Secondary Objective: To compare the pain scores in the gabapentin and placebo groups as recorded by pain score right now and pain score average for previous 24 hours.
Eligibility| Ages Eligible for Study: | 1 Year to 18 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Participant is enrolled on Total XVI
- Participant is 1 year of age or older
- Participant has symptoms of NP/PN with onset no more than 7 days after one of the following vincristine doses: protocol week 1, week 2 (induction), week 7 (reinduction I), or week 17 (reinduction II).
- Patient is expected to receive 2 doses of vincristine in weekly intervals as outlined by the Total XVI protocol while on study drug (i.e. no known dosage reductions or planned missed doses).
Participant is able and willing to take oral medications.
Exclusion Criteria:
- Previous participation in this study
- Participant is receiving gabapentin for another indication at the time of diagnosis of NP/PN or has received gabapentin previously.
- Pregnancy. Female participants of childbearing potential must have documented negative urine or serum pregnancy test result not older than 7 days. Male patients with reproductive potential will be counseled not to procreate during the study.
- Impaired renal function: decreased eGFR (<60ml/min/1.73m^2 as estimated by the revised Schwartz equation)
- Participant has allergy or other contraindication for either morphine or gabapentin therapy.
- Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.
Contacts and Locations| Contact: Doralina Anghelescu, MD | 866-278-5833 | info@stjude.org |
| United States, Tennessee | |
| St. Jude Children's Research Hospital | Recruiting |
| Memphis, Tennessee, United States, 38105 | |
| Contact: Doralina Anghelescu, MD 866-278-5833 info@stjude.org | |
| Principal Investigator: Doralina Anghelescu, MD | |
| Principal Investigator: | Doralina Anghelescu, MD | St. Jude Children's Research Hospital |
More Information
Additional Information:
No publications provided
| Responsible Party: | St. Jude Children's Research Hospital |
| ClinicalTrials.gov Identifier: | NCT01506453 History of Changes |
| Other Study ID Numbers: | TINALL |
| Study First Received: | January 4, 2012 |
| Last Updated: | December 18, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by St. Jude Children's Research Hospital:
|
Acute Lymphoblastic Leukemia Neuropathy Neuropathic Pain Vincristine TOTAL XVI Protocol |
Additional relevant MeSH terms:
|
Leukemia Leukemia, Lymphoid Precursor Cell Lymphoblastic Leukemia-Lymphoma Neuralgia Peripheral Nervous System Diseases Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Pain Neurologic Manifestations Nervous System Diseases Neuromuscular Diseases |
Signs and Symptoms Vincristine Gabapentin Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Antineoplastic Agents, Phytogenic Antineoplastic Agents Therapeutic Uses Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on May 16, 2013